| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC5081 | Apitolisib Featured | GDC-0980 (RG7422) is a potent, class I PI3K inhibitor for PI3Kα/β/δ/γ with IC50 of 5 nM/27 nM/7 nM/14 nM, respectively. Also a mTOR inhibitor with Ki of 17 nM, and highly selective versus others PIKK family kinases. |
|
| DC8410 | GNE-317 Featured | GNE-317 is a potent, brain-penetrant PI3K inhibitor. |
|
| DC8257 | GNE 477 Featured | GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with IC50 of 4 nM for PI3Kα, Kiapp is 21 nM for mTOR. |
|
| DC8502 | GNE-490 Featured | GNE-490 is a highly selective pan-PI3K inhibitor and demonstrates selectivity over mTOR. |
|
| DC7953 | GNE-493 Featured | GNE-493 is a potent, selective, and orally available dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively. |
|
| DC9515 | PI3K inhibitor GS1059615 | GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively. |
|
| DC7141 | Omipalisib Featured | GSK2126458 is a highly selective and potent inhibitor of PI3K with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2 , respectively. |
|
| DC9943 | PI3Kδ inhibitor GS2269557 | GSK-2269557 is a potent and selective PI3Kδ inhibitor over the closely related isoforms. |
|
| DC9944 | PI3Kδ inhibitor GS2292767 | GSK2292767 is a potent and selective PI3Kδ inhibitor. |
|
| DC2070 | GSK690693 Featured | GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively. |
|
| DC10061 | PI4KA inhibitor-A1 Featured | GSK-A1 is a potent inhibitor of PI4KA. In vitro using HEK-AT1 cells, GSK-A1 had an IC50 of about 3 nM. |
|
| DC7705 | HTH-01-015 Featured | HTH-01-015 is a selective inhibitor of NUAK1 kinase with an IC50 value of 100 nM. |
|
| DC7156 | IC-87114 Featured | IC-87114 was the first isoform-selective PI3K inhibitor. p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM). |
|
| DC11151 | ICSN3250 hydrochloride | ICSN3250 (ICSN-3250) hydrochloride is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors. |
|
| DC11150 | ICSN3250 | ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors. |
|
| DC7171 | INK-128(Sapanisertib) Featured | INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms. |
|
| DC7873 | INK-055 (PI3Kγ inhibitor 1) | INK055 is a dual PI3Kg/d inhibitor. |
|
| DC5072 | Duvelisib (IPI-145, INK1197) Featured | IPI-145 is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. |
|
| DC9829 | IPI-549 Featured | IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. |
|
| DC10746 | KDU691 Featured | KDU691 is a PI4K inhibitor. |
|
| DC3101 | Ku-0063794 | KU-0063794 is a potent and highly specific mTOR inhibitor for both mTORC1 and mTORC2 with IC50 ~10 nM. |
|
| DC12386 | Leniolisib (CDZ173) Featured | Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor currently in phase II/III clinical trials for the treatment of immunodeficiency disorders. |
.gif)
|
| DC10754 | LX2343 Featured | LX-2343 is a novel non-ATP competitive PI3K inhibitor, negatively regulating AKT/mTOR signaling, thus promoting autophagy, and increasing A-beta clearance. |
|
| DC1058 | LY294002 Featured | LY294002 is a PI3K inhibitor for p110α, p110δ and p110β with IC50 of 0.5 μM, 0.57 μM and 0.97 μM, respectively. |
|
| DC10219 | LY3023414 Featured | LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
|
| DC7210 | LY-303511(Nv-128) Featured | LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K. |
|
| DC10015 | MELK-8a Featured | MELK-8a is a novel MELK inhibitor. |
|
| DC11465 | MELK-T1 Featured | MELK-T1 is a potent and selective inhibitor of protein kinase MELK. |
|
| DC7465 | MK-2206 2HCl Featured | MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2. |
|
| DC11405 | MK-3903 Featured | MK-3903 is a potent and selective AMP-activated protein kinase (AMPK) activator with an EC50 of 8 nM. generation of catalytically active enzyme. |
|
